A Study of Mirdametinib in People With Central Nervous System Tumors

Full Title

Phase 1/2 Trial of Mirdametinib in Patients with MAPK Pathway Mutant Central Nervous System Tumors

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Anna Piotrowski’s office at 212-610-0483.

Protocol
26-103
Phase
Phase I/II (phases 1 and 2 combined)
Investigator
Anna F. Piotrowski
Co-Investigators
Eli L. Diamond
Thomas J. Kaley
Diseases
Brain Tumors, Primary › Primary Central Nervous System Lymphoma
Locations
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau
ClinicalTrials.gov ID
NCT07539441
ClinicalTrials.gov
Visit ClinicalTrials.gov for full clinical trial description